Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion

The retreatment rate was lower in the ranibizumab group after the initial three injections. Therefore, bevacizumab may be considered a clinically effective alternative to ranibizumab for the initial three loading doses in patients with BRVO- related ME, particularly when cost is a limiting factor.